A Phase 3 interventional study of ezetimibe (+) simvastatin and Comparator : rosuvastatin calcium in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 12th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 26th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 618 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 21st largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 39th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Arm 1: drug
Drug: ezetimibe (+) simvastatin · Drug: Comparator: Placebo (unspecified)
Arm 2: active comparator
Drug: Comparator : rosuvastatin calcium · Drug: Comparator: Placebo (unspecified)
Drug pages: Ezetimibe · Simvastatin
ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
Also known as: MK0653A, Vytorin®
rosuvastatin 10mg. The treatment duration will be 6 weeks.
rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment
Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment
The percentage of participants who achieved a target LDL-C goal of \< 100 mg/dL, of \<70 mg/dL, and of \<77 mg/dL at study endpoint after six weeks of treatment. The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.
Time frame: after 6 weeks of treatment
Percent Change From Baseline in Total Cholesterol
Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in Triglycerides.
Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)
Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)
Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in Apolipoprotein B
Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein
Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
Time frame: Baseline and 6 weeks
Phase IV First Participant In: 31-Mar-2007; Last Participant Last Visit 11-Mar-2008 85 centers worldwide (EX US) Eligible participants include those on a stable dose of one of the following: rosuvastatin 5 mg; simvastatin 20 mg, 40 mg; atorvastatin 10, 20 mg; pravastatin 40 mg; fluvastatin 80 mg.
| Milestone | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Started | 314 | 304 |
| Completed | 301 | 295 |
| Not completed | 13 | 9 |
| Withdrew: Adverse event | 8 | 6 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 |
Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment | -27.66 (-30.27 to -25.04) | -16.94 (-19.61 to -14.28) |
The percentage of participants who achieved a target LDL-C goal of \< 100 mg/dL, of \<70 mg/dL, and of \<77 mg/dL at study endpoint after six weeks of treatment. The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.
| Percent of participant population | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| LDL-C <100 | 72.46 | 56.23 |
| LDL-C <70 | 25.25 | 11.11 |
Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol | -17.53 (-19.36 to -15.71) | -10.33 (-12.19 to -8.47) |
Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in Triglycerides. | -11.00 (-15.25 to -6.80) | -5.26 (-9.92 to -1.17) |
Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) | 2.12 (0.34 to 3.89) | 3.03 (1.22 to 4.85) |
Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) | -23.42 (-25.81 to 21.03) | -14.01 (-16.46 to -11.57) |
Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio | -27.41 (-30.42 to -24.40) | -17.82 (-20.89 to -14.75) |
Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio | -17.76 (-19.94 to -15.57) | -11.51 (-13.74 to -9.28) |
Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B | -17.87 (-20.05 to -15.70) | -9.77 (-11.99 to -7.55) |
Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.
| percent change from baseline | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein | -8.33 (-16.67 to 0.00) | 0.00 (-7.14 to 6.25) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetemibe + Simvastatin | — | — | — |
| Rosuvastatin | — | — | — |
| Event | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| Chest painGeneral disorders | 0/312 | 2/304 |
| Epileptic seizureNervous system disorders | 0/312 | 1/304 |
| Skin eruptionSkin and subcutaneous tissue disorders | 0/312 | 1/304 |
| In-stent arterial restenosisInjury, poisoning and procedural complications | 0/312 | 1/304 |
| CholangitisHepatobiliary disorders | 1/312 | 0/304 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/312 | 0/304 |
| Subarachnoid hemorrhageNervous system disorders | 1/312 | 0/304 |
| Event | Ezetemibe + Simvastatin | Rosuvastatin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/312 | 1/304 |
| DyspepsiaGastrointestinal disorders | 3/312 | 1/304 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/312 | 2/304 |
| Abdominal painGastrointestinal disorders | 2/312 | 2/304 |
| NauseaGastrointestinal disorders | 2/312 | 0/304 |
| VomittingGastrointestinal disorders | 2/312 | 0/304 |
| BronchitisInfections and infestations | 2/312 | 0/304 |
| Abdominal pain upperGastrointestinal disorders | 1/312 | 1/304 |
| Dry mouthGastrointestinal disorders | 0/312 | 1/304 |
| AstheniaGeneral disorders | 0/312 | 1/304 |
| Age, Continuous(years) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Mean | 63.2 (38 to 82) | 63.1 (27 to 80) | 63.15 (27 to 82) |
| Sex: Female, Male(Participants) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Female | 129 | 119 | 248 |
| Male | 185 | 185 | 370 |
| Race/Ethnicity, Customized(participants) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| White | 314 | 302 | 616 |
| Black | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 43 | 80 |
| Not Hispanic or Latino | 277 | 261 | 538 |
| Apolipoprotein B(mg/dL) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Median | 1.20 ± 0.20 | 1.18 ± 0.21 | 1.19 ± 0.21 |
| C Reactive Protein(mg/dL) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Median | 0.16 ± 0.26 | 0.15 ± 0.26 | 0.16 ± 0.26 |
| High Density Lipoprotein-Cholesterol(mg/dL) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Mean | 1.43 ± 0.37 | 1.43 ± 0.36 | 1.43 ± 0.36 |
| Low Density Lipoprotein-Cholesterol (LDL-C)(mg/dL) | Ezetemibe + Simvastatin | Rosuvastatin | Total |
|---|---|---|---|
| Mean | 3.21 ± 0.42 | 3.24 ± 0.44 | 3.23 ± 0.43 |
5 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
Ran from Feb 2007 to primary completion in Mar 2008, 13 months.
Results were first posted in Jun 2009, 1 year 3 months after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin